Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06171542
Other study ID # IHTSC CTM Project HC22-2
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date December 22, 2022
Est. completion date April 30, 2025

Study information

Verified date December 2023
Source Indiana Hand to Shoulder Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

CTM Biomedical markets and distributes decellularized particulate human placental connective-tissue matrix products, intended solely for homologous use to supplement or replace damaged or inadequate connective-tissue. These are structural tissue allografts processed according to the criteria contained in 21CFR 1271.10(a) for regulation solely under section 361 of the Public Health Service Act. The goal of this study is to determine the success rate of a single, image guided glenohumeral CTM injection (for radiographically confirmed glenohumeral osteoarthritis at follow up intervals of 1, 2, 3, 4, 6, 9, and 12 months. This will be measured using the Likert Pain Scale (LPS) and Oxford Shoulder Score (OSS). Secondary goals are to identify if certain demographic or imaging factors exist that predict early symptom recurrence requiring additional intervention, defined as a second connective tissue matrix injection, a subsequent corticosteroid injection, or arthroplasty.


Description:

A recent prospective study by our center identified a clinically meaningful and statistical improvement after corticosteroid injection in the Oxford Shoulder Score and VAS pain scores in patients with glenohumeral arthritis2. CTM Biomedical markets and distributes decellularized particulate human placental connective-tissue matrix products, intended solely for homologous use to supplement or replace damaged or inadequate connective-tissue. These are structural tissue allografts processed according to the criteria contained in 21CFR 1271.10(a) for regulation solely under section 361 of the Public Health Service Act. CTM Flow is decellularized particulate human placental connective-tissue matrix provided in a vial. Osteoarthritis creates pain due to damaged tissues. CTM has been approved to supplement and replace damaged tissues. It is not replacing the damaged cartilage with new cartilage, but rather with other connective tissues. Previous unpublished studies in tonsil surgery and knee arthritis surgery have shown improvement from the CTM injections. Image guided injection of the glenohumeral joint has been shown to be more accurate than blind in-office injections and will thus be used in this study3. The goal of this study is to determine the success rate of a single, image guided glenohumeral (GH) CTM injection (for radiographically confirmed glenohumeral osteoarthritis at follow up intervals of 1, 2, 3, 4, 6, 9, and 12 months. This will be measured using the Likert Pain Scale (LPS) and Oxford Shoulder Score (OSS). Secondary goals are to identify if certain demographic or imaging factors exist that predict early symptom recurrence requiring additional intervention, defined as a second connective tissue matrix injection, a subsequent corticosteroid injection, or arthroplasty.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date April 30, 2025
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Radiographic documented Glenohumeral osteoarthritis (grade 1-3) 2. Males or females age 18 or older 3. Patients receiving a CTM injection for their initial treatment 4. Patients who can consent to be a part of this study 5. Patients who are able keep up regular communication through phone calls or electronic PROs Exclusion Criteria: 1. Inflammatory Arthritis 2. Brachial Plexopathy 3. Cervical spine abnormalities such as radiculopathies 4. age less than 18 years 5. those unable to keep up monthly communication through phone calls and/or electronic PROs 6. Absence of glenohumeral osteoarthritis 7. Pregnancy or breastfeeding 8. Non-english speaking

Study Design


Intervention

Device:
CTM Injection
All glenohumeral joint injections will be performed by a physician under the guidance of either ultrasound or fluoroscopy to ensure and document intra-articular needle placement. 2cc of CTM Flow will be injected. The glenohumeral joint will be injected with the medication under the discretion of the treating surgeon.

Locations

Country Name City State
United States Indiana Hand to Shoulder Center Indianapolis Indiana

Sponsors (2)

Lead Sponsor Collaborator
Indiana Hand to Shoulder Center CTM Biomedical

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Likert Pain Scale PROM 12 Months
Primary Oxford Shoulder Score PROM 12 Months
See also
  Status Clinical Trial Phase
Completed NCT03540030 - Opioid-Free Shoulder Arthroplasty Phase 4
Recruiting NCT06025331 - Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA? N/A
Recruiting NCT06153381 - Virtual Rehabilitation Assistant Via Instant Messaging Communication to Promote Adherence to Rehabilitation After Reverse Shoulder Replacement N/A
Recruiting NCT04762667 - Individual Preoperative Planning for RSA N/A
Recruiting NCT06025448 - Is MIO-RSA Noninferior to BIO-RSA When it Comes to Mechanical Implant Stability? N/A
Completed NCT03854357 - Subscapularis Strength After Total Shoulder Arthroplasty N/A
Recruiting NCT05408065 - Comparison of the Analgesic Effect of 2 Shoulder Infiltrations N/A
Recruiting NCT05048264 - Effect of Corticosteroid Injections on Blood Glucose
Recruiting NCT05395819 - Clinical Evaluation of Reverse Versus Anatomic Shoulder Arthroplasty Techniques in the Treatment of Osteoarthritis N/A
Recruiting NCT06381791 - CBD for Pain Following Orthopedic Shoulder Surgery Phase 1/Phase 2
Active, not recruiting NCT04405297 - A Disease-based Treatment Study for Diagnosed Osteoarthritis Utilizing Adipose-derived Regenerative Cells
Not yet recruiting NCT05868330 - Comparison of Interscalene Catheter to Single Injection Interscalene Blocks for Total Shoulder Arthroplasties N/A
Recruiting NCT05675527 - PRP for Glenohumeral Osteoarthritis Phase 4
Recruiting NCT06319911 - AETOS Shoulder System
Withdrawn NCT03474510 - Effective Pain Management During Shoulder Replacement Surgery With EXPAREL Phase 4
Completed NCT05043493 - Effect of PRP as Therapy for Shoulder Osteoarthritis N/A
Recruiting NCT05788614 - Retroversion in Reverse Shoulder Arthroplasty N/A
Not yet recruiting NCT06435494 - Cross-sectorial Use of Patient-Reported Outcomes in Chronic Degenerative Shoulder Conditions N/A
Withdrawn NCT04285606 - Effect of Postop Rehab Methods on Outcomes Following Reverse Shoulder Arthroplasty N/A
Recruiting NCT04984291 - Zimmer Biomet Shoulder Arthroplasty PMCF N/A